OpenText Cybersecurity’s 2024 Ransomware Survey: Supply Chain Attacks Surge, Ransom Payments Persist

Companies Still Struggling with Ransomware Attacks OpenText Releases 2024 Global Ransomware Survey Results WATERLOO, ON, Oct. 10, 2024 /PRNewswire/ — OpenText™ (NASDAQ: OTEX), (TSX: OTEX) today released its third annual 2024 Global Ransomware Survey, which reveals the current state of ransomware attacks, including ransom payments, the impact of software supply chain attacks, and generative AI….

Read More

Join Us on a Coastal Adventure: Eco-Wave Power CEO Visits Taiwan’s East Coast for Exciting Power Station Sale Signing!

Welcome Ms. Inna Braverman to Taiwan! A Look at the Future of Wave Energy Technology Exciting Developments in Sustainable Energy It’s an exciting time for the sustainable energy industry as Ms. Inna Braverman, the Founder and CEO of Eco Wave Power, arrives for an official visit to the site where Eco Wave Power’s innovative technology…

Read More

O3 Mining Partners with Top Marketing and Market-Making Firms for Enhanced Growth

O3 Mining Announces Marketing Consulting Agreements O3 Mining Inc. (TSXV: OIII) (OTCQX: OIIIF) (“O3 Mining” or the “Corporation”) has recently made an announcement regarding certain agreements for marketing consulting, promotional, and market-making services. The Corporation has entered into a marketing consulting services agreement with Spark Newswire Inc. (“Spark”) for promotional services in accordance with the…

Read More

Revolutionizing the Lending Industry: S&P Global Market Intelligence’s Expanded Product Suite Shortens Loan Settlement Times

S&P Global Market Intelligence Expands Lending Solutions Suite Driving Innovation in Global Lending Markets NEW YORK, Oct. 10, 2024 /PRNewswire/ — S&P Global Market Intelligence, provider of information services and solutions to the global markets, announced today an expansion of its lending solutions suite to drive innovation across the global lending markets. The enhanced solutions…

Read More

New Breakthrough Treatment for Crohn’s Disease and Ulcerative Colitis: Tremfya (Guselkumab) Shows Promising Results in Both Biologic-Naive and Biologic-Refractory Patients

TREMFYA®: A Breakthrough in Treatment for Inflammatory Bowel Diseases Exciting News for Patients with Ulcerative Colitis and Crohn’s Disease In a groundbreaking development, Johnson & Johnson has announced that TREMFYA® (guselkumab) has been approved by the U.S. FDA for the treatment of ulcerative colitis and is currently under review for Crohn’s disease. This marks a…

Read More

Veris Health, a Pavmed Subsidiary, Receives $1.8 Million NIH Grant to Revolutionize Cancer Treatment

Charmingly eccentric, full of personality, and designed for maximum reader engagement Grant to Fund Research for Medically Underserved Cancer Patients NEW YORK, Oct. 10, 2024 /PRNewswire/ — PAVmed Inc. (Nasdaq: PAVM) (“PAVmed” or the “Company”) a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital…

Read More